VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit [Accessibility Statement] Skip NavigationNEW YORK, Feb. 27, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.So what: If you purchased Vistagen common s ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Ultragenyx a ...

New York, New York--(Newsfile Corp. - February 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contin ...

Core Viewpoint - Pomerantz Law Firm is investigating potential securities fraud and unlawful business practices by Ashford Hospitality Trust, Inc. and its officers or directors [1] Group 1: Company Actions - On January 13, 2026, Ashford announced the extension of its Highland mortgage loan secured by 18 hotels [1] - To maintain liquidity while evaluating strategic alternatives, Ashford suspended preferred dividends for various series of preferred stock, including those declared for record holders as of December 31, 2025, payable on January 15, 2026 [1] Group 2: Market Reaction - Following the announcement, Ashford's stock price decreased by $0.35 per share, representing an 8.1% decline, closing at $3.97 per share on January 13, 2026 [1]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4- ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false and/or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors are encouraged to join the class action, which allows for potential compensation without upfront costs through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against PennyMac Financial Services, Inc. (PFSI) for possible violations of securities laws, particularly regarding misleading statements and undisclosed information [1] Financial Performance - PennyMac reported a pretax income of $37.3 million for its servicing segment in Q4 2025, a significant decrease from $157.4 million in the previous quarter and $87.3 million in Q4 2024 [1] - The company's retax income, excluding valuation-related items, was $47.8 million, reflecting a 70% decline from the prior quarter, primarily due to increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates led to higher prepayment activity [1] Market Reaction - Following the announcement of its financial results, PennyMac's shares experienced a sharp decline of 33.3% the next day [1]

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against PomDoctor Ltd. (NASDAQ: POM) on behalf of investors who purchased securities between October 9, 2025, and December 11, 2025, alleging that the company misled investors regarding its business operations [1]. Group 1: Allegations Against PomDoctor Ltd. - The lawsuit claims that PomDoctor was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [1]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1]. - As a result of these actions, the positive statements made by the defendants about PomDoctor's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their motions with the court by April 7, 2026 [1]. - A lead plaintiff acts on behalf of other class members in directing the litigation, but participation is not required to be eligible for recovery [1]. - All representation in this case is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [1].

Market Overview - U.S. stocks opened 2026 with modest gains, with the Dow Jones Industrial Average and S&P 500 rising, while the Nasdaq Composite lagged behind, reflecting cautious optimism after a strong 2025 for equities [1] - Trading volumes were light, indicating a rebound from late-December weakness [1] Sector Performance - Chipmakers, particularly Nvidia and Micron, led early gains due to ongoing enthusiasm around AI demand, although weakness in several megacap technology and consumer discretionary stocks limited broader market gains [2] Economic Outlook - Investors are focusing on upcoming economic data and Federal Reserve signals to assess the outlook for rates and growth in 2026, with strategists cautioning that early January market movements may not dictate future trends [3] Bullish Stocks - Nike, Inc. shares rose nearly 3% following insider buying, which is seen as a vote of confidence in the company's turnaround strategy, with CEO Elliott Hill purchasing approximately $1 million in shares [4] - Energy Fuels Inc. exceeded its production guidance, mining over 1.6 million pounds of uranium and projecting Q4 sales around 360,000 pounds, generating approximately $27 million in revenue [6] - A potential SpaceX IPO in 2026 could significantly impact the market, potentially leading to capital rotation from Tesla as investors buy SpaceX shares, while ultimately benefiting Elon Musk-linked companies [5] Bearish Stocks - U.S.-listed Chinese tech stocks, including Alibaba, JD.com, and PDD Holdings, declined due to thin holiday trading volumes and disappointing economic data from China, reflecting broader market weakness [7] - Ultragenyx Pharmaceutical and Mereo BioPharma shares fell to 52-week lows after a late-stage clinical trial for a bone disease therapy failed to meet its primary endpoint [8] - Corcept Therapeutics shares dropped sharply following an FDA refuse-to-file letter for its investigational drug relacorilant, which surprised investors and led to reassessment of the company's regulatory pathway [9]

Upgrades - Argus upgraded BHP Group (BHP) to Buy from Hold with a price target of $68, citing firming prices for iron ore, copper, and coal as the global economy improves [1] Downgrades - Jefferies downgraded Mereo BioPharma (MREO) to Hold from Buy with a price target of $0.50, down from $7, due to Setrusumab missing primary endpoints in trials [2] - RBC Capital downgraded DigitalBridge (DBRG) to Sector Perform from Outperform with a price target of $16, down from $23, following SoftBank's acquisition announcement at $16 per share [3] Initiations - Stephens initiated coverage of Commvault (CVLT) with an Overweight rating and a $162 price target, highlighting its evolution in data protection and transition to Software-as-a-Service [4] - Stephens initiated coverage of Rubrik (RBRK) with an Overweight rating and a $105 price target, noting its attractive growth outlook in data protection and data security [4] - Stephens initiated coverage of Varonis (VRNS) with an Equal Weight rating and a $40 price target, emphasizing its growth potential in data security as a Software-as-a-Service platform [4] - Freedom Capital initiated coverage of Ero Copper (ERO) with a Buy rating and a $32 price target, citing its high-grade, low-cost asset portfolio in Brazil [4] - H.C. Wainwright initiated coverage of Terra Innovatum (NKLR) with a Buy rating and a $25 price target, believing its use of off-the-shelf components will reduce regulatory barriers [4]